undamentalytics Newsletter

Newamsterdam Pharma Co N.V. valuation and forecast

Explore the models for Newamsterdam Pharma Co N.V., adjust their assumptions and compare your own valuation with the platform's.

Stock price today

Loading chart…

Third-party market data · may be delayed

Fair value per share

Under review: every model's value for Newamsterdam Pharma Co N.V. is far from the share price, which usually points to a data problem (a merger, a share-count change, a one-off) rather than a bargain or a bubble.

Price vs value

Under review: limited reported history: available models are shown without a Buy/Hold/Sell rating. We'll show the comparison once resolved.

Analyst recommendations

16 analysts, Oct 2026
Buy1594%
Hold16%
Sell00%

Monthly trend

  1. Oct 202631216
  2. Sep 202631216
  3. Aug 202631216
  4. Jul 202631216

Counts of recommendations published by analysts covering Newamsterdam Pharma Co N.V., by month. Source: Aggregated broker recommendations (third-party data). Aggregated counts only: we do not reproduce any firm's recommendation or price target, and these are not Fundamentalytics ratings.

Price history

Loading chart…

Third-party market data · may be delayed

NAMS valuation questions

How does Fundamentalytics value Newamsterdam Pharma Co N.V.?
We use the models that fit Newamsterdam Pharma Co N.V.'s business and available financial data. Each model has its own assumptions and data requirements. The calculator explains which models are available and lets you adjust their inputs.

Data: SEC EDGAR filings, retrieved Invalid Date. Method: how we value companies. Disclosures: research and recommendations disclosure. Back to Newamsterdam Pharma Co N.V.